Daily Endocrinology Research Analysis
Three studies reshape current thinking in metabolic endocrinology: adipocyte-derived extracellular vesicles (EVs) were shown to restore central leptin sensitivity and induce weight loss in obese mice; a global biopsy-based cohort in MASLD validated non-invasive fibrosis tests as strong predictors of mortality and events; and human translational work demonstrated impaired ketone body-driven mitochondrial oxidation across insulin-resistant organs. Together, these advance mechanisms, risk stratific
Summary
Three studies reshape current thinking in metabolic endocrinology: adipocyte-derived extracellular vesicles (EVs) were shown to restore central leptin sensitivity and induce weight loss in obese mice; a global biopsy-based cohort in MASLD validated non-invasive fibrosis tests as strong predictors of mortality and events; and human translational work demonstrated impaired ketone body-driven mitochondrial oxidation across insulin-resistant organs. Together, these advance mechanisms, risk stratification, and potential therapeutic targets.
Research Themes
- Adipose-brain axis mechanisms and leptin resistance
- Non-invasive fibrosis risk stratification in MASLD
- Mitochondrial metabolic flexibility and ketone oxidation in insulin resistance
Selected Articles
1. Adipocyte-derived extracellular vesicles are key regulators of central leptin sensitivity and energy homeostasis.
Adipocyte-derived EVs carry a miRNA repertoire that sensitizes leptin signaling by suppressing negative regulators; loss of these miRNAs fosters leptin resistance in obesity. Engineered EVs targeting the CNS restored central leptin responsiveness and produced significant weight loss in obese mice, illuminating an adipose-brain axis mechanism and a therapeutic vector.
Impact: This study identifies a concrete, transferable molecular cargo within adipocyte EVs that restores central leptin sensitivity and demonstrates in vivo efficacy with targeted EV delivery. It reframes leptin resistance as an EV-mediated, modifiable process with translational potential.
Clinical Implications: While preclinical, the work opens a path to EV-based therapeutics aimed at reversing leptin resistance, a core barrier to obesity treatment. It also suggests biomarkers (EV miRNA signatures) for assessing leptin sensitivity and treatment response.
Key Findings
- Adipocyte-derived EVs contain miRNAs that enhance leptin signaling by inhibiting negative feedback regulators.
- Obesity is associated with loss of leptin-sensitizing miRNAs in Ad-EVs, contributing to leptin resistance and weight gain.
- Engineered EVs targeted to the CNS delivered leptin-sensitizing miRNAs, reversing central leptin resistance and inducing significant weight loss in obese mice.
Methodological Strengths
- Mechanistic dissection of EV miRNA cargo with functional validation in vivo.
- Targeted EV engineering enabling CNS delivery and causal testing of leptin sensitization.
Limitations
- Preclinical models in mice; human safety, biodistribution, and durability are unknown.
- Potential off-target effects and immunogenicity of engineered EVs require evaluation.
Future Directions: Define EV dose, schedule, and safety in large animals; profile EV miRNA biomarkers of leptin sensitivity in humans; and initiate first-in-human studies for obesity with leptin resistance phenotyping.
The exact mechanisms underlying leptin resistance, the central mechanism of obesity, remain elusive. Herein, we demonstrate that adipocyte-derived extracellular vesicles (Ad-EVs) serve as key regulatory factors of hypothalamic circuits governing food intake and body weight by modulating leptin responsiveness. Specifically, we identified a subset of microRNA (miRNA) within Ad-EVs that exerts leptin-sensitizing effects by inhibiting negative feedback regulators of leptin receptor signaling. Loss of these leptin-sensitizing miRNAs in Ad-EVs contributes to leptin resistance and subsequent weight gain in obesity. Of note, we developed engineered EVs modified with specific Ad-EV membrane proteins for targeted delivery of leptin-sensitizing miRNAs to the central nervous system, which reversed central leptin resistance and induced significant weight loss in obese mice. These findings highlight the critical role of Ad-EVs in central leptin sensitivity regulation, offering new insights into the role of the adipose tissue-brain axis in maintaining energy balance and potential pharmacological targets for obesity treatment.
2. Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study.
In 17,792 biopsy-confirmed MASLD patients, advanced fibrosis was common (35%) and tightly associated with type 2 diabetes. Both histologic fibrosis and non-invasive fibrosis tests independently predicted mortality and clinical events over a mean 6.6 years, supporting broad adoption of NITs for risk stratification.
Impact: This global, biopsy-based cohort robustly validates non-invasive fibrosis markers for prognostication and quantifies diabetes’ contribution to fibrosis and outcomes, informing clinical pathways at scale.
Clinical Implications: Routine fibrosis risk assessment using validated NITs should be integrated into MASLD care to identify high-risk patients and co-manage type 2 diabetes and obesity aggressively to reduce events.
Key Findings
- Among 17,792 MASLD patients, 35% had advanced fibrosis (≥F3).
- Type 2 diabetes prevalence increased stepwise with fibrosis stage (28% in F0 to 70% in F4; p<0.0001).
- Both histologic fibrosis and NITs independently predicted mortality and liver-related clinical events over 6.6 years.
- Five-year mortality rose from 2.1% overall to 8.3% in cirrhosis and exceeded 10% in those with high-risk NIT scores.
Methodological Strengths
- Very large, global, biopsy-confirmed cohort with long follow-up.
- Consistent multivariable associations and validation of non-invasive tests across regions.
Limitations
- Observational design with potential residual confounding and selection bias from biopsy cohorts.
- Regional heterogeneity in obesity associations may limit generalizability of specific risk weights.
Future Directions: Prospective implementation studies testing NIT-guided care pathways and integration with diabetes/obesity management; evaluation of thresholds triggering antifibrotic trials.
BACKGROUND: Advanced histologic fibrosis is a major predictor of mortality in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to identify advanced fibrosis clinical determinants across diverse MASLD populations and to assess the prognostic value of non-invasive markers (NITs) of fibrosis for adverse outcomes. METHODS: The Global MASLD (G-MASLD) enrolled biopsy-confirmed MASLD patients with clinical, histologic, and non-invasive test (NIT) data. Factors associated with the presence of advanced histologic fibrosis (F3-F4) in MASLD and clinical outcomes were assessed. RESULTS: There were 17,792 MASLD patients. Advanced fibrosis (≥F3) was present in 35%. The prevalence of type 2 diabetes (T2D) increased stepwise with fibrosis stage, from 28% in F0 to 70% in F4 (trend p<0.0001). Independent predictors of advanced fibrosis included older age, T2D, and obesity, although the association with obesity varied by region. Among patients with follow-up (mean 6.6 y), 6.5% died and 10.1% experienced a clinical event. Older age, male sex, T2D, and obesity were independent predictors of both mortality and clinical events (p<0.05). Fibrosis severity, whether defined histologically or by NITs, was strongly associated with higher risks of death and liver-related outcomes (all aHR>1.0, p<0.001). Five-year mortality was 2.1% overall, rising to 8.3% in patients with cirrhosis, and exceeded 10% among those with high-risk NIT score values. CONCLUSIONS: In this large global biopsy-based MASLD cohort, advanced fibrosis was highly prevalent and strongly linked to T2D. Both histologic fibrosis and NITs were independent predictors of mortality and clinical outcomes, underscoring the prognostic value of fibrosis assessment with non-invasive tests.
3. Impaired mitochondrial ketone body oxidation in insulin resistant states.
Across human heart, skeletal muscle, and liver (and in mouse kidney), ketone body-supported mitochondrial respiration is significantly reduced in insulin-resistant states. This establishes a cross-organ signature of impaired metabolic flexibility and positions ketone respirometry as a sensitive functional biomarker.
Impact: By directly quantifying ketone-driven OXPHOS across human tissues, the study links insulin resistance to a definable mitochondrial deficit, informing biomarker development and therapeutic targeting of metabolic inflexibility.
Clinical Implications: Ketone body respirometry could refine phenotyping and risk profiling in T2D, obesity, and MASLD, and guide trials of interventions aimed at restoring mitochondrial flexibility (nutritional, pharmacologic, or exercise).
Key Findings
- Ketone body-driven mitochondrial OXPHOS capacity was ~30% lower in human heart and skeletal muscle in T2D versus controls.
- The relative contribution of ketone bodies to maximal OXPHOS was reduced in T2D heart (~25%) and skeletal muscle (~50%).
- Hepatic β-hydroxybutyrate-driven OXPHOS was 29% lower in obese humans with steatosis; obese mice showed ~15% reduction in kidney cortex.
Methodological Strengths
- High-resolution respirometry across multiple human tissues with disease-state comparisons.
- Cross-species validation increasing biological plausibility and generalizability.
Limitations
- Sample sizes per tissue cohort and covariate control are not detailed in the abstract.
- Cross-sectional ex vivo measures preclude causal inference and do not test therapeutic reversibility in humans.
Future Directions: Establish standardized ketone respirometry protocols for clinical research, test interventions that restore ketone-driven OXPHOS, and link tissue-level deficits to whole-body outcomes.
BACKGROUND: Reduced mitochondrial respiratory function has been implicated in metabolic disorders like type 2 diabetes (T2D), obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD), which are tightly linked to insulin resistance and impaired metabolic flexibility. However, the contribution of the ketone bodies (KBs) β-hydroxybutyrate (HBA) and acetoacetate (ACA) as substrates for mitochondrial oxidative phosphorylation (OXPHOS) in these insulin resistant states remains unclear. METHODS: Targeted high-resolution respirometry protocols were applied to detect the differential contribution of HBA and ACA to OXPHOS capacity in heart, skeletal muscle, kidney, and liver of distinct human or murine cohorts with T2D, obesity, and MASLD. FINDINGS: In humans with T2D, KB-driven mitochondrial OXPHOS capacity was ∼30% lower in the heart (p < 0.05) and skeletal muscle (p < 0.05) compared to non-diabetic controls. The relative contribution of KBs to maximal OXPHOS capacity in T2D was also lower in both the heart (∼25%, p < 0.05) and skeletal muscle (∼50%, p < 0.05). Similarly, in kidney cortex from high-fat diet-induced obese mice, both the absolute and relative contribution of KBs to OXPHOS capacity was ∼15% lower (p < 0.05). Finally, hepatic HBA-driven mitochondrial OXPHOS capacity was 29% lower (p < 0.05) in obese humans with hepatic steatosis compared to humans without. INTERPRETATION: Mitochondrial KB-driven OXPHOS capacity is impaired in insulin resistant states in various organs in absolute and relative terms, likely reflecting impaired mitochondrial metabolic flexibility. Our data suggest that KB respirometry can provide a sensitive readout of impaired mitochondrial function in diabetes, obesity, and MASLD. FUNDING: German Research Foundation, German Diabetes Center, German Federal Ministry of Health, Ministry of Culture and Science of the state of North Rhine-Westphalia, German Federal Ministry of Education and Research, German Center for Diabetes Research, German Heart Foundation, German Diabetes Society, Christiane-and-Claudia Hempel Foundation, European Community and Schmutzler Stiftung.